Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2023-03-09 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
关于公司选举职工代表监事的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the election of an employee representative supervisor to the company's supervisory board. It includes details about the election meeting, voting results, and a personal resume of the elected individual. There is no financial data, no mention of financial results, no regulatory certifications, or report publications. The content focuses on board/management information, specifically about the supervisory board composition. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS.
2023-03-09 Chinese
独立董事提名人声明（陈凌）
Board/Management Information Classification · 95% confidence The document is a public statement from a nominator regarding the nomination of an independent director candidate for the company's board. It details the qualifications, compliance with laws and regulations, and independence criteria of the nominee. There is no financial data, earnings information, or report publication mentioned. The content focuses on board/management information, specifically about director nomination and compliance with regulatory requirements for independent directors. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is sufficient and contains detailed statements about the nominee's qualifications and compliance, confirming it is not a brief announcement or a regulatory filing but a substantive management-related disclosure.
2023-03-09 Chinese
2022年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled '2022 年度监事会工作报告' which translates to '2022 Supervisory Board Work Report'. It details the supervisory board's activities, meetings, opinions on various financial reports (annual report, quarterly reports, internal control reports), and oversight of company operations and compliance during 2022. It includes references to the audit report and internal control evaluations but does not itself contain full financial statements or detailed financial data. The document is a report from the supervisory board summarizing their oversight work rather than the company's annual report or audit report itself. The length is 2638 characters, which is relatively short and consistent with a supervisory board work report. This type of document is best classified under Management Reports (MDA), as it provides management's detailed explanation of company oversight, financial results, and business trends from the supervisory board perspective.
2023-03-09 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policy by 普洛药业股份有限公司. It details the reasons for the change, the previous and new accounting policies, the impact on financial statements, and includes opinions from the board of directors, independent directors, and the supervisory board. The document does not contain full financial statements or comprehensive financial performance data but rather focuses on the policy change and its implications. It is not a full annual or interim report, nor is it a certification or a brief announcement of a report. Given the content and length (3384 characters), it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-03-09 Chinese
年度关联方资金占用专项审计报告
Audit Report / Information Classification · 95% confidence The document is titled as a special audit explanation regarding non-operating fund occupation and other related party fund transactions for the year 2022. It references an audit report issued by a certified public accounting firm with a standard unqualified opinion on the 2022 financial statements. The document includes a summary table of related party fund transactions and states it is prepared according to regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The document is a standalone audit report focusing on a specific audit area related to funds and related party transactions, not a full annual report or general financial statement. It is not a brief announcement or a certification letter but a detailed audit explanation and summary. Therefore, it fits the category of Audit Report / Information (AR). The document length is short but contains substantive audit content, not merely an announcement or certification. FY 2022
2023-03-09 Chinese
关于拟续聘会计师事务所的公告
Audit Report / Information Classification · 90% confidence The document is an announcement regarding the proposed reappointment of an accounting firm (auditor) for the company's 2023 financial report and internal control audit. It details the qualifications, independence, and integrity of the accounting firm and the approval process by the board and independent directors. The document does not contain any actual financial statements or audit results, nor does it present a full audit report. Instead, it is a formal announcement about the intention to rehire the auditor for the upcoming audit period. The document length is short (2222 characters), and it serves as a notification rather than a full audit report. Therefore, it fits best under the category of Audit Report / Information (AR) as it relates to audit matters but is not a full annual report or financial statement filing. FY 2023
2023-03-09 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.